EMA – Page 153 – Pharma.Tips

Cleaning validation failure during inspection readiness: GMP investigation and containment strategy

Addressing Cleaning Validation Failures During Inspection Readiness: An In-depth GMP Investigation and Containment Strategy In the complex landscape of pharmaceutical manufacturing, the integrity of cleaning validation processes is paramount, especially…

Biologic glycosylation shift (CQAs) outside trend after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Investigating Biologic Glycosylation Shift (CQAs) Following Equipment Qualification Update In the highly regulated world of pharmaceutical manufacturing, deviations such as a biologic glycosylation shift that deviates from established trends can…

Stability degradation after cleaning cycle change: CAPA aligned to regulatory expectations

Understanding Stability Degradation Following Modifications to Cleaning Cycles In the pharmaceutical manufacturing environment, stability degradation can arise unexpectedly after changes to cleaning cycles. Such incidents carry significant implications for product…

Biologic freeze-thaw cycle deviation during deviation investigation board review: single-use systems risk controls, leachables review, and supplier oversight actions

Addressing Deviations in Biologic Freeze-Thaw Cycles: An Operational Guide In the dynamic landscape of pharmaceutical manufacturing, deviations related to the freeze-thaw cycle of biologics can significantly impact product quality and…

Carryover contamination risk after cleaning cycle change: GMP investigation and containment strategy

Addressing the Risk of Carryover Contamination Following Changes in Cleaning Cycles Changes to cleaning cycles are designed to enhance efficiency, yet they may inadvertently introduce carryover contamination risks, especially within…

Biologic cell culture contamination event during commercial manufacturing campaign: single-use systems risk controls, leachables review, and supplier oversight actions

Addressing Biologic Cell Culture Contamination Events During Commercial Manufacturing Campaigns Biologic cell culture contamination events can pose significant risks to the integrity and safety of pharmaceutical manufacturing campaigns. In this…

Potency variability during multi-product campaign: GMP investigation and containment strategy

GMP Investigation and Containment Strategy for Potency Variability in Multi-Product Campaigns In the highly regulated world of pharmaceutical manufacturing, the ability to maintain consistent potency across multi-product campaigns is paramount.…

Biologic cold chain excursion impact after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Investigating the Impact of Cold Chain Excursions on Biologics Following Equipment Qualification Updates The integrity of the cold chain is critical in the manufacturing and distribution of biologics. When deviations…

Stability degradation during inspection readiness: CAPA aligned to regulatory expectations

“`html Addressing Stability Degradation During Inspection Readiness through Effective CAPA Stability degradation can significantly affect pharmaceutical products, particularly hormonal products, prior to regulatory inspections. The implications often necessitate a thorough…

Biologic charge variant shift (CEX) OOS after equipment qualification update: viral safety and contamination response plan with inspection-ready evidence

Investigating Biologic Charge Variant Shift OOS Following Equipment Qualification Changes In the intricate world of pharmaceutical manufacturing, particularly concerning biologics, deviations such as Out of Specification (OOS) results can arise…

Blend uniformity OOS in hormonal manufacturing: CAPA aligned to regulatory expectations

“`html Investigation of Blend Uniformity OOS in Hormonal Manufacturing: Ensuring Regulatory Compliance Through CAPA In pharmaceutical manufacturing, particularly in the production of hormonal products, out-of-specification (OOS) results can pose significant…

Biologic viral clearance validation gap during stability pull at 3/6/12 months: CAPA package with CQA/CPP risk assessment and effectiveness verification

Addressing Gaps in Biologic Viral Clearance Validation During Stability Pulls at 3, 6, and 12 Months In the pharmaceutical industry, ensuring the quality and safety of biologics is paramount. When…